CAJ | 학술논문

Objective. To improve the treatment of tumors, we studied the combined effects of docetaxel and batimastat(BB-94) on mouse forestomach carcinoma (MFC), and compared them with doxorubicin.Methods and results. In vitro, growth curve analysis, MTF assay and clonogenic assay used to determine thecvtotoxic effect of cocetaxel or/and BB-94 on MFC cell showed that docetaxel but not BB-94 had a significantcytotoxicity, and the effect of docetaxel wasn't enhanced by BB-94. In early stage MFC tumor model, obviousantitumor effect of docetaxel or doxorubicin given i. v. at maximum tolerated dose (MTD, docetaxel: 20mg/kg;doxorubicin: 6mg/kg) every 4 days for 3 injections (q4d x3), even that of BB-94 (30mg/kg i. p. qd ×20)was observed. Tumorgrowth inhibition was greater for docetaxel-batimastat (96.0%) than for doxorubicin - batimas-tat (88.0%), docetaxel (89.0%), doxorubicin (68.0%) and BB-94 (33.0%), and the effect of docetaxelcould be potentiated by BB-94. Docetaxel also showed activity against advanced stage MFC tumor in dose - depen-dent manner, and was more effective at MTD than doxorubicin with 4/5 regressions, 46.5 days tumor growth de-lay and 2.81og10 turmor cell kill.Conclusion. O ur results suggest that in the MFC model with dose and schedule used, docetaxel is an effec-tive cytotoxic new drug against MFC tumor and BB-94 enchances the antitumor activity of docetaxel.